Flatiron Health Showcases AI-Driven Real-World Evidence Research in Oncology

A LinkedIn post from Flatiron Health highlights new oncology research the company is presenting at the ISPOR Annual meeting, with a focus on generating rigorous, scalable evidence from real-world data. The post describes work using large language models to integrate PSA and imaging data for deriving real-world progression events in prostate cancer, aiming to improve accuracy and completeness of clinical endpoints.

The post also notes a study evaluating four digital-twin modeling approaches to predict survival in advanced non-small cell lung cancer, suggesting Flatiron is exploring advanced predictive analytics in high-value tumor types. Another project applies the newly published VALID framework to assess the quality of an LLM-derived prostate cancer real-world dataset, indicating an emphasis on methodological robustness and data validation.

In addition, the post references a collaborative pilot with Friends of Cancer Research examining external-control arms based on real-world data, emphasizing that outcomes depend on data quality, consistent methodology, and careful planning. For investors, these initiatives suggest Flatiron is investing in AI-driven real-world evidence, which could enhance the attractiveness of its data and analytics platforms to biopharma, payers, and regulators, potentially supporting long-term revenue growth and reinforcing its position in oncology RWE and health economics research.